Coldstream Capital Management’s GSK GSK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$806K Buy
14,576
+1,361
+10% +$73.8K 0.01% 524
2025
Q4
$651K Sell
13,215
-5,954
-31% -$278K 0.01% 605
2025
Q3
$830K Buy
19,169
+8,926
+87% +$349K 0.01% 521
2025
Q2
$396K Buy
10,243
+7,797
+319% +$298K 0.01% 757
2025
Q1
$94.8K Buy
+2,446
New +$89.5K ﹤0.01% 1385
2022
Q2
$204K Buy
+3,758
New +$207K 0.01% 729
2017
Q4
Sell
-4,666
Closed -$237K 320
2017
Q3
$237K Buy
+4,666
New +$237K 0.03% 268

Other funds holding GSK

Coldstream Capital Management's GSK Position: Q1 2026 in Review

Coldstream Capital Management increased its GSK (GSK) stake by 10% in Q1 2026, buying an estimated $73.8K and bringing the position to 14,576 shares worth $806K. The position accounts for 0.01% of the portfolio, ranked #524.

Coldstream Capital Management first reported a position in GSK in Q3 2017 and has held it in 7 quarters since. The position peaked at $830K in Q3 2025. 1,034 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

  • Coldstream Capital Management held 14,576 shares of GSK worth $806K as of Q1 2026.
  • Coldstream Capital Management bought 1,361 GSK shares in Q1 2026, an estimated $73.8K.
  • GSK made up 0.01% of Coldstream Capital Management's portfolio in Q1 2026, its #524 holding.
  • Coldstream Capital Management first reported a position in GSK in Q3 2017 and has held it in 7 quarters since.
  • Coldstream Capital Management's GSK position peaked at $830K in Q3 2025.
  • 1,034 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Coldstream Capital Management's 13F filing for Q1 2026, filed 8 May 2026.